{"prompt": "['8.5.2 Hepatitis Screening', 'Blood samples will be collected at screening from all patients in order to perform', 'hepatitis B surface antigen and hepatitis C antibody (immunoglobulin G) testing. Test', 'results will be sent to the screening site and must be reviewed before the Day 1 visit.', 'Any patient who tests positive for hepatitis B or C will be excluded from participating in', 'the study. Details regarding sample collection, processing, and shipping can be found', 'in the study reference manual.', '8.5.3 HIV Screening', 'Patients are required to provide blood samples for HIV virus types 1 and 2 testing. Test', 'results will be sent to the screening site and must be reviewed before the Day 1 visit.', 'Any patient who tests positive for HIV will be excluded from participating in the study.', 'Patients will be informed of positive HIV results and referred for follow-up testing and', 'counseling, and health authorities will be notified of positive HIV results consistent with', 'federal, state, and local laws. Details regarding sample collection, processing, and', 'shipping can be found in the study reference manual.', '8.5.4 Urine Drug and Alcohol Screening', 'Qualitative urine drug (amphetamines, barbiturates, benzodiazepines, cannabinoids', '[THC], cocaine metabolites, methadone, opiates, phencyclidine, propoxyphene) and', 'alcohol tests will be performed. Any patient who tests positive for drugs of abuse or', 'alcohol test at the screening visit, or presents evidence of either withdrawal from or', 'acute intoxication with cocaine, opiates, amphetamines (including methamphetamine),', 'alcohol, barbiturates, or hallucinogens or similar compounds will be excluded. The', 'urine drug screen may be repeated once based on investigator judgment and reviewed', 'for medical appropriateness by the Medical Monitor as part of the screening', 'adjudication process.', 'Note: Previous occasional use of alcohol or cannabis (but not synthetic', 'marijuana/K2/Spice) or prescribed psychotropic (e.g., benzodiazepine, opiate) is', 'allowed as long as the level of use does not meet DSM-5 criteria for any moderate or', 'severe substance use disorder within the 12 months prior to screening and the use of', 'alcohol or cannabis is not considered to be the precipitating factor of the current', 'depressive episode, in the opinion of the investigator and any prescribed psychotropic', 'is', 'accompanied by evidence of prescription; patients are required to abstain from alcohol', 'and drug use during the study.', 'Further information regarding sample collection, processing, and shipping can be found', 'in the study reference manual.', 'Intra-Cellular Therapies, Inc. Confidential', '39 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['Intra-Cellular Therapies, Inc. Confidential', '40 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['Intra-Cellular Therapies, Inc. Confidential', '41 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}